BRAF and glioblastoma: Since Dabrafenib is a clinically used agent for Ep‐GBM patients with the BRAF V600E mutation, we further investigated whether NU7441 treatment enhanced the anti‐tumor efficiency of Dabrafenib toward Ep‐GBM‐like tumors.